| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964526 | Vaccine | 2014 | 7 Pages |
Abstract
The safety and immunogenicity of LJEV co-administered with measles vaccine in Sri Lankan infants is similar to that seen in other populations, and our results support use of LJEV at 9 months of age. Live SA 14-14-2 vaccine is now prequalified by the WHO for use in infants in Asia, and other countries may wish to introduce LJEV to combat this devastating disease.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pushpa Ranjan Wijesinghe, M.R. Nihal Abeysinghe, Sutee Yoksan, Yafu Yao, Benli Zhou, Lei Zhang, Mansour Yaich, Kathleen M. Neuzil, John C. Victor,